Interstitial inflammation and pulmonary fibrosis in COVID-19: The potential role of cytostatic therapy for severe lung injuryстатьяЭлектронная публикация
Информация о цитировании статьи получена из
Scopus
Статья опубликована в журнале из списка Web of Science и/или Scopus
Дата последнего поиска статьи во внешних источниках: 26 июня 2024 г.
Аннотация:Highlights•Cyclophosphamide can be considered relatively safe and reasonably effective in severe lung damage in COVID-19.•Cyclophosphamide may reduce interstitial inflammation, thus preventing the development of pulmonary fibrosis.•No severe side effects were observed during low-dose cyclophosphamide therapy in our study